Thank you. Welcome to the annual meeting of stockholders of Celldex Therapeutics, being held this year by remote communication. Please note that any non-historical statements the company will make today will constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from these statements as a result of a number of risks and uncertainties, including the risks that Celldex has cited in its most recent 10-K and 10-Q filings with the Securities and Exchange Commission, and that Celldex typically cites in its press releases. I would like to remind everyone that this meeting is not a public forum for the purposes of the SEC's Regulation FD. As a result, while we will provide you with general background information about Celldex, we will not be providing any material non-public information at this meeting. I will now turn the meeting over to Anthony Marucci, Celldex's Co-Founder, President, and Chief Executive Officer, and a member of the Board of Directors. Anthony? Thank you, Sarah. Good morning, everyone. I'd like to take a moment to thank each employee and each Director for their continued hard work. I would also like to thank our shareholders for your continued support and your participation in today's virtual annual meeting. With that said, it is now 9:02 A.M., and this meeting is now called to order. I would like to introduce our other Board members in attendance today. I am joined by Mr. Keith Brownlie, Ms. Cheryl Cohen, Mr. Herbert Conrad, Dr. Rita Jain, Mr. James Marino, Dr. Garry Neil, Mr. Harry Penner, and Ms. Denice Torres. We also have present our representatives from our auditor, PricewaterhouseCoopers; Anna Hagberg, who will act as our independent Inspector of Elections; Sarah Cavanaugh, our Senior Vice President of Corporate Affairs and Administration; and Sam Martin, our Senior Vice President, Chief Financial Officer, and Secretary. The company's bylaws provide that any business brought before an annual meeting by a stockholder, which is not specified in the notice of the meeting, must be submitted in writing in advance to the Secretary of the company, and that that notice meet certain requirements. The company did not receive any such notice, as such, voting will be confined to the four proposals outlined in the proxy statement. Prior to the meeting, I appointed Sam Martin as acting Secretary of the meeting. I asked Sam to include with the minutes of the meeting, a copy of the affidavit of distribution, a certified list of stockholders, a notice of meeting and proxy statement previously mailed to all stockholders, which we refer to as the proxy materials. The notice of the meeting and the proxy statement were filed with the Securities and Exchange Commission on April 29th, 2026. The proxy statement describes the record date for this meeting and the number of eligible votes of common stock outstanding on that date. Prior to the meeting, I appointed Anna Hagberg as Inspector of Election, and she has taken the appropriate oath. At this point, I will call for a formal portion of our meeting to order. Will the Inspector of Election please report on the existence of a quorum? The board of directors selected April 27th, 2026, as the record date for the annual meeting. On the record date, there were 78,492,072 shares of common stock outstanding. A total of 65,086,035 shares of common stock are present in person or by proxy at this meeting, representing at least a majority of the voting power. Accordingly, a quorum is present. Since a quorum is present, we may now proceed to the business of the meeting. To assure an orderly meeting, I will first entertain motions for the four proposals to be presented at today's meeting, and the polls will be open for voting. I will then provide a brief update on the company's recent progress and address questions related to the four proposals, our development programs, and our overall business to the extent that they are germane to the meeting and do not require the disclosure of material non-public information. Only validated stockholders will be able to ask questions in the designated field on the web portal. Out of consideration for others, please limit yourself to two questions. We will attempt to answer as many questions as time allows, but as always, we are available to answer your questions after the meeting as well. I will then declare the polls closed and ask the Inspector of Election to provide a preliminary voting tally. The final votes will be reported by the company in an 8-K. There are four proposals being presented for you today. As indicated in the proxy statement, the board of directors has nominated each of myself, Keith Brownlie, Cheryl Cohen, Herbert Conrad, Dr. Rita Jain, James Marino, Dr. Garry Neil, Harry Penner, and Denice Torres for election as a director. As a stockholder, I move to elect Anthony Marucci, Keith Brownlie, Cheryl Cohen, Herbert Conrad, Dr. Rita Jain, James Marino, Dr. Garry Neil, Harry Penner, and Denice Torres as directors for the terms described in the proxy statement. I second the motion. The second proposal is to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31st, 2026. As a stockholder, I move to approve the second proposal. I second the motion. The third proposal is to approve an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of shares reserved for issuance thereunder by 3,400,000 shares to 12,900,000 shares. As a stockholder, I move to approve the third proposal. I second the motion. The fourth proposal is an advisory and non-binding proposal to approve the compensation of the company's named executive officers as disclosed in the proxy statement. As a stockholder, I move to approve the fourth proposal. I second the motion. Each director nominee will be elected if he or she receives a majority of the votes cast during the meeting or by proxy at this meeting. Proposals two, three, and four will be approved if they receive the affirmative vote of the majority of the votes cast of such a proposal. I assume that everyone present has voted by means of proxy or voted via telephone or the internet. If there is anyone present who would like to vote now, either because they have not voted or because they wish to change their vote, please vote now by using the voting buttons on the virtual meeting interface. Stockholders who have sent in proxies or voted via telephone or internet and do not want to change their vote do not need to take any further action. All proxies received in the mail have been voted as instructed. If no direction was given, the shares were voted for each of the proposals I just listed. Thank you. I would like to now take a few moments to provide a brief company update before we address the questions. Mast cell targeting strategies are rapidly emerging as powerful therapeutic approaches in inflammatory diseases. We are leading the field here, leveraging our expertise in antibody drug development and driving groundbreaking science while advancing our pipeline across multiple programs and preparing our business for the next stage of development, which is becoming a fully integrated commercial company. Let me start first with an update of the barzolvolimab program. We announced earlier this year that we completed enrollment of our phase III studies in CSU six months ahead of schedule. Over 1,900 patients were enrolled, the largest program conducted in antihistamine-refractory CSU, including patients with advanced therapy experience or refractory CSU. We look forward to reporting top-line data from these studies in the fourth quarter of this year and remain focused on completing preparations to support bringing this much-needed treatment to patients. Based on our results from our phase II studies, barzolvolimab has the potential to deliver best-in-class and best-in-disease clinical profile, symptom-free complete control, and dramatic improvements in both quality of life and angioedema. We have seen similar stellar results from our phase II study in two of the most common forms of inducible urticaria, cold urticaria, and symptomatic dermatographism. Barzolvolimab was the first drug to demonstrate clinical benefit in a large randomized placebo-controlled study in these two forms of inducible urticaria, again with high rates of complete response and dramatic improvements in quality of life. In late 2025, we initiated a phase III study of these indications, and enrollment is off to a good start. We also completed enrollment in phase II studies of prurigo nodularis and atopic dermatitis. We anticipate results from the PN study in the summer and from the AD study later this year. Earlier this month, we reported our first-in-human data for CVX-622, a novel bispecific antibody combining mast cell depletion and TSLP inhibition. Data demonstrated that CVX-622 induced rapid, durable dose-dependent reductions in serum tryptase, indicative of mast cell depletion and is well-tolerated at all doses. CVX-622 is currently being studied in asthma. Based on these data, we plan to initiate additional proof-of-concept studies in multiple indications where both mast cells and TSLP play a pathogenic role, focusing next on allergic rhinitis and food allergies. Importantly, the CVX-622 proof-of-concept study also validated the significant potential of targeting soluble stem cell factor. Celldex is the first company to directly demonstrate that neutralizing soluble stem cell factor can selectively inhibit KIT signaling in mast cells. This approach provides a promising anchor mechanism around which we intend to develop a robust portfolio of bispecific candidates designed to overcome the heterogeneity inherited in the pathophysiology of many inflammatory diseases. It also further reinforces our leadership in driving groundbreaking mast cell science. Importantly, the company is well-capitalized. We ended the first quarter of 2026 on March 31st with cash on hand of $451.5 million. In April, we raised an additional $345 million in a public offering of common stock, which will fund all current planned activities through 2028. We appreciate the opportunity to share these highlights with you now, and we look forward to connecting with you later again this year on our future company developments. At this time, we will entertain questions that shareholders wish to raise regarding the proposals submitted at this meeting or regarding Celldex in general, to the extent remain and not otherwise addressed in my remarks. Our representatives from our independent registered public accounting firm are also present and available to answer appropriate questions from stockholders. At this point, there are no questions. At this point, I will end the question and answer period. Stockholders should feel free to write to investor relations, care of the company, or email us at ir@celldex.com if they have questions or comments that they wish to address to the company or me. I will be closing the polls in a moment, please finalize voting if you are voting now. I now declare the polls closed. The Inspector of Elections will now report the preliminary results of the proposals. Each of Anthony Marucci, Keith Brownlie, Cheryl Cohen, Herbert Conrad, Dr. Rita Jain, James Marino, Dr. Garry Neil, Harry Penner, and Denice Torres was elected and received a majority of the votes cast in the election. The proposal to ratify PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for fiscal year 2026, the proposal to approve an amendment to our 2021 Omnibus Equity Incentive Plans, and the proposal to approve the non-binding advisory vote on the executive compensation of the company's named executive officers as described in the proxy statement, was approved by the affirmative vote of the majority of the votes cast on each such proposal. The precise number of votes will be set forth in my written report. Thank you, Anna. At this point, I will entertain a motion to adjourn the meeting. Moved. I second the motion. The meeting is adjourned. Again, thank you all for attending. We wish you well and hope you enjoy your summer. Operator, at this time, you may close the call. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.